{
    "name": "molnupiravir",
    "comment": "Investigational",
    "other_names": [
        "Lagevrio"
    ],
    "classes": [
        "Antivirals",
        "SARS-CoV-2"
    ],
    "source": "https://reference.medscape.com/drug/lagevrio-molnupiravir-4000252",
    "pregnancy": {
        "common": [
            "Not recommended during pregnancy",
            "Based on animal data, fetal harm may occur when administered to pregnant females ",
            "No available human data are available on use in pregnant females to evaluate the risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Verify pregnancy status in females of childbearing potential",
            "Prescribing healthcare provider must communicate the known and potential benefits and the potential risks of using molnupiravir during pregnancy to the pregnant individual",
            "May only be prescribed to pregnant individuals after the prescribing healthcare provider has determined that the benefits would outweigh the risks for that individual patient",
            "If used during pregnancy, prescribing healthcare provider must document potential risks and benefits were communicated"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "There are maternal and fetal risks (eg, preeclampsia, eclampsia, preterm birth, premature rupture of membranes, venous thromboembolic disease, fetal death) associated with untreated COVID-19 in pregnancy "
                ]
            },
            {
                "type": "Pregnancy surveillance program ",
                "description": [
                    "Program monitors pregnancy outcomes in individuals exposed to molnupiravir during pregnancy",
                    "Prescribing healthcare provider must document that pregnant individuals were made aware of the ",
                    ", OR",
                    "Merck Sharp & Dohme’s pregnancy surveillance program at 1-877-888-4231 or "
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of childbearing potential: Use a reliable method of contraception correctly and consistently, as applicable during treatment and for 4 days after final dose",
                    "Males with partners of childbearing potential: Use a reliable method of contraception correctly and consistently during treatment and for at least 3 months after final dose; risk beyond 3 months after last dose is unknown; studies on the risks >3 months are ongoing"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Oral administration to pregnant rats during organogenesis resulted in embryofetal lethality and teratogenicity at 8x the human NHC exposures at the recommended human dose (RHD) and reduced fetal growth at ≥3x the human NHC exposure at the RHD",
                    "Oral administration to pregnant rabbits during organogenesis resulted in reduced fetal body weights at 18x the human NHC exposure at the RHD"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on the presence of molnupiravir or its metabolites in human milk",
            "NHC was detected in the plasma of nursing pups from lactating rats administered molnupiravir ",
            "It is unknown whether molnupiravir affects the breastfed infants or has effects on milk production",
            "Not recommended during treatment and for 4 days after final dose",
            "Consider interrupting breastfeeding, and consider pumping and discarding breast milk during treatment and for 4 days after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Based on animal reproduction studies, molnupiravir may cause fetal harm when administered to pregnant individuals",
                "If used during pregnancy, prescribing healthcare providers must communicate to the patient the known and potential benefits and the potential risks of molnupiravir use during pregnancy",
                "Verify pregnancy status in females of childbearing potential",
                "Healthcare providers must provide the patient/caregiver with electronic or hard copy of the “Fact Sheet for Patients and Caregivers” prior to patientreceiving molnupiravir and must document that patient/caregiver has been given an electronic or hard copy of the “Fact Sheet for Patients and Caregivers”"
            ],
            "specific": [
                {
                    "type": "Pregnancy surveillance program",
                    "description": [
                        "Program monitors pregnancy outcomes in individuals exposed to molnupiravir during pregnancy",
                        "Prescribing healthcare provider must document that pregnant individuals were made aware of Merck Sharp & Dohme’s pregnancy surveillance program at 1-877-888-4231 or ",
                        "pregnancyreporting.msd.com ",
                        "Those who agree to participate in the program and allow the healthcare provider to disclose patient-specific information to Merck Sharp & Dohme must provide a full name and contact information",
                        "Pregnant individuals exposed to molnupiravir can also report the exposure by contacting the phone number or website listed above"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None have been identified based on the limited available data on the emergency use authorized under this EUA"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "There are limited clinical data available; serious and unexpected adverse events may occur that have yet to be reported",
                "May cause fetal harm when administered to pregnant females"
            ],
            "specific": [
                {
                    "type": "Bone and cartilage toxicity",
                    "description": [
                        "Not authorized for use in patients aged <18 years owing to possible effects on bone and cartilage growth",
                        "Bone and cartilage toxicity was observed in rats after repeated dosing ",
                        "Safety and efficacy have not been established in pediatric patients"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Selected Grade",
            "percent": "3"
        },
        {
            "name": "and",
            "percent": "4"
        },
        {
            "name": "laboratory abnormalities in chemistry",
            "percent": null
        },
        {
            "name": "ALT",
            "percent": null
        },
        {
            "name": "AST",
            "percent": null
        },
        {
            "name": "creatinine",
            "percent": null
        },
        {
            "name": "and lipase",
            "percent": null
        },
        {
            "name": "and hematology",
            "percent": null
        },
        {
            "name": "hemoglobin",
            "percent": null
        },
        {
            "name": "platelets",
            "percent": null
        },
        {
            "name": "and leukocytes",
            "percent": null
        },
        {
            "name": "Death or a life",
            "percent": null
        },
        {
            "name": "threatening adverse event",
            "percent": null
        },
        {
            "name": "A medical or surgical intervention to prevent death",
            "percent": null
        },
        {
            "name": "a life",
            "percent": null
        },
        {
            "name": "threatening event",
            "percent": null
        },
        {
            "name": "hospitalization",
            "percent": null
        },
        {
            "name": "disability",
            "percent": null
        },
        {
            "name": "or congenital anomaly",
            "percent": null
        },
        {
            "name": "Inpatient hospitalization or prolongation of existing hospitalization",
            "percent": null
        },
        {
            "name": "A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions",
            "percent": null
        },
        {
            "name": "or",
            "percent": null
        },
        {
            "name": "A congenital anomaly",
            "percent": null
        },
        {
            "name": "birth defect",
            "percent": null
        }
    ]
}